Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the "Private Placement") of up to 20,000,000 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of up to $11,000,000. Each Unit will be comprised of one common share (each, a "Share ...

Vancouver, British Columbia, February 27, 2026 - TheNewswire — Noveris Health Sciences Inc. (the “Company”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today that JJK Holdings Ltd. (“JJK”) acquired a convertible debenture of the Company in the principal amount of CAD $7,878,792 (the “Debenture”) previously held by Pioneer Garage Limited (“Pioneer”) (previously announced as having been acquired by Ray Van Empel, the principal shareholder of Pioneer), pursuant to a privately negotiated purchase agreement ( ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .There are several major investor concerns around the current market. One should be valuation levels, which are exceedingly stretched, viewed from a historical lens. Tariffs are another significant worry, given tariff policies are extrem ...

Core Insights - INmune Bio is a clinical stage biotechnology company focused on developing therapies for neuroinflammation in neurodegenerative diseases, with its lead program XPro1595 being a first-in-class selective soluble TNF inhibitor [1] Group 1: Clinical Development - The objective of the recent webinar was to demonstrate how the clinical results from the Phase II MINDFuL trial will inform the registration program for XPro1595 [2] - A productive end of Phase II meeting with the FDA confirmed alignment on the core elements of the Phase III registration program [2] Group 2: Trial Design and Outcomes - The MINDFuL trial was a strategic proof-of-concept study designed to address two critical variables: biologic signal and patient selection in Alzheimer's disease [3] - The trial aimed to determine if XPro1595 shows biologic activity in patients with Alzheimer's disease and inflammation biomarkers, and whether the right patient population for a registration trial could be identified [3] - Results indicated that XPro1595 demonstrated biologic activity and validated a precision medicine roadmap for the Phase III registration program [3]

Core Insights - Puma Biotechnology (PBYI) reported fourth-quarter 2025 adjusted earnings of 29 cents per share, exceeding the Zacks Consensus Estimate of 24 cents, but down from 43 cents in the same quarter last year [1] - Total revenues for the fourth quarter reached $75.5 million, surpassing the Zacks Consensus Estimate of $68 million, and reflecting a 28% year-over-year increase [2] Financial Performance - Product revenues from Nerlynx totaled $59.9 million in Q4, up nearly 10% year over year, beating estimates of $54 million [4] - Royalty revenues surged 232% year over year to $15.6 million [4] - Total operating costs for the quarter were $58.4 million, an increase of 28% year over year [4] - For the full year 2025, total revenues were $228.4 million, slightly down from $230.5 million in the previous year [6] Guidance and Projections - For 2026, net product revenues are projected to be between $194 million and $198 million, with total revenues expected to range from $214 million to $221 million, which is below the Zacks Consensus Estimate of $235.7 million [7][8] - The company anticipates a net loss of approximately $8 million to $10 million for Q1 2026 [12] Pipeline Developments - Puma Biotechnology is developing alisertib, an aurora kinase A inhibitor, for hormone receptor-positive breast cancer and small-cell lung cancer [13] - The company is conducting a phase II study (ALISCA-Lung1) for alisertib as a monotherapy for extensive-stage SCLC, with interim data expected in Q2 2026 [14] - Another phase II study (ALISCA-Breast1) is underway for alisertib in combination with endocrine treatment for HER2-negative, hormone receptor-positive metastatic breast cancer, with initial data also expected in Q2 2026 [15] Market Performance - PBYI's shares have increased by 154.2% over the past year, compared to the industry's rise of 19.9% [9]

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings. Sign up here. Reporting by Pragyan Kalita in Bengaluru; Editing by Sahal Muhammed Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut Februa ...

On February 17, 2026, Casdin Capital disclosed a buy of 1,662,193 shares of Relay Therapeutics (NASDAQ:RLAY), an estimated $11.86 million trade based on quarterly average pricing, in its Form 13F filing. What happened According to an SEC filing dated February 17, 2026, Casdin Capital increased its holding in Relay Therapeutics by 1,662,193 shares, bringing its total to 13,003,574 shares. The estimated transaction value was $11.86 million, calculated using the quarterly average share price. The quarter-en ...

Shares of Inventiva S.A. Sponsored ADR (IVA) have gained 3.6% over the past four weeks to close the last trading session at $6.55, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.48 indicates a potential upside of 136.3%.The mean estimate comprises 12 short-term price targets with a standard deviation of $5.56. While the lowest estimate of $8.80 indicates a 34.4% increase fr ...

Group 1 - The article discusses the importance of staying updated on stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The Haggerston BioHealth group provides insights on catalysts, buy and sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-specific analyses for major pharmaceutical companies [1]

This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results were reported across multiple therapeutic areas, including radiographic and non-radiographic axial spondyloarthritis, microcystic lymphatic malformations, pulmonary arterial hypertension, and obesity. Here's a closer look at the details. FDA Approvals & Rejections Armata Pharma Secures FDA QIDP Designation for AP-SA02 Armata Pharmaceuticals, ...